Clinical trial
Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or…
NCT00488709 · PETHEMA Foundation, Other · Completed
Key facts
| NCT number | NCT00488709 |
|---|---|
| Title | Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia |
| Official title | FLAT: Fludarabine, Cytarabine and Topotecan in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia |
| Acronym | FLAT |
| Lead sponsor | PETHEMA Foundation, Other |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Acute Myeloid Leukemia |
| Intervention type | Drug |
| Interventions | Topotecan, Fludarabine, Cytarabine |
| Enrollment | 47 |
| Start date | May 1, 2003 |
| Completion | Apr 1, 2007 |
| First posted | Jun 20, 2007 |
| Last update posted | Nov 18, 2008 |
| Countries | Spain |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: